|
Status |
Public on Aug 03, 2023 |
Title |
M14_ARoe_Dabrafenib |
Sample type |
RNA |
|
|
Source name |
M14 melanoma cell line; AR overexpression + Dabrafenib
|
Organism |
Homo sapiens |
Characteristics |
gender: male group: AR overexpression + Dabrafenib cell line: M14 melanoma cell line
|
Treatment protocol |
ARoe and LacZ melanoma cells were treated with 500nM Dabrafenib or with a vehicle control (DMSO) 48h prior to RNA extraction.
|
Growth protocol |
Human melanoma A375, M14 and WM9 cell lines were cultured in RPMI (RPMI1640 with L-glutamine; Corning) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich). For transduction, cells were treated with ARoe or LacZ lentiviruses overnight. Transduced cells were selected using blasticidin.
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was extracted using Direct-zol RNA MiniPrep kit (Zymo Research) coupled with DNase treatment. RNA quality was verified by Bioanalyzer (Agilent Technologies).
|
Label |
biotin
|
Label protocol |
Affymetrix protocol
|
|
|
Hybridization protocol |
Affymetrix protocol
|
Scan protocol |
Arrays were scanned on GS300 scanner (Thermo Fisher Scientific) with AGCC Scan Control Software.
|
Data processing |
.CEL files were summarized using RMA function in the R package oligo with background correction and quantile normalization. Gene IDs were mapped using the Chip-annotation package clariomdhumantranscriptcluster.db and differential expression analysis was performed with limma, using the formula ~treatment + cell_line . The cutoffs for the new signatures (BRAF and “extended”) were FC > 1.5, and adj-p < 0.1
|
|
|
Submission date |
Mar 25, 2022 |
Last update date |
Aug 03, 2023 |
Contact name |
Paola Ostano |
Organization name |
Fondazione Edo ed Elvo Tempia
|
Street address |
via Malta 3
|
City |
Biella |
ZIP/Postal code |
13900 |
Country |
Italy |
|
|
Platform ID |
GPL23126 |
Series (2) |
GSE199405 |
Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance [Clariom_1] |
GSE232697 |
Androgen Receptor is a Determinant of Melanoma BRAFi/MEKi Resistance |
|